Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly’s weight-loss pill, orforglipron, shows promising results in trials, offering a needle-free alternative to injectables like Ozempic and Mounjaro. In a major study, people who took the drug ...

Those on the highest 36 mg dose of the medicine on average lost 12.4 per cent of their body weight at 72 weeks ...

Eli Lilly, the manufacturer of a new weight-loss pill (an alternative to popular weight-loss jabs), says the drug could be ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.

A weight loss pill called orforglipron has had some successful results from the human trial stage, so when could we see it on the NHS?

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...